Article Information
History
- September 1, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Madison Stoddard1,
- Lin Yuan1,
- Sharanya Sarkar2,
- Shruthi Mangalaganesh3,
- Ryan P. Nolan4,
- Dean Bottino5,
- Greg Hather6,
- Natasha S. Hochberg7,
- Laura F. White8 and
- Arijit Chakravarty1,*
- 1Fractal Therapeutics, Cambridge, MA, USA
- 2Dartmouth College, Hanover, NH, USA
- 3Monash University, Melbourne, VIC, AUS
- 4Halozyme Therapeutics, San Diego, CA, USA
- 5Takeda Pharmaceuticals, Cambridge, MA, USA
- 6Sage Therapeutics, Cambridge, MA, USA
- 7Boston University Medical Center, Boston, MA, USA
- 8Boston University School of Public Health, Boston, MA, USA
- ↵*Corresponding author Email: arijit{at}fractal.tx (A.C.)
Posted September 01, 2022.
Heterogeneity in vaccinal immunity to SARS-CoV-2 can be addressed by a personalized booster strategy
